ATHA vs. PASG, VXRT, ALGS, ADAP, PSTX, AURA, JSPR, TRML, AGEN, and AVXL
Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Passage Bio (PASG), Vaxart (VXRT), Aligos Therapeutics (ALGS), Adaptimmune Therapeutics (ADAP), Poseida Therapeutics (PSTX), Aura Biosciences (AURA), Jasper Therapeutics (JSPR), Tourmaline Bio (TRML), Agenus (AGEN), and Anavex Life Sciences (AVXL). These companies are all part of the "biological products, except diagnostic" industry.
Passage Bio (NASDAQ:PASG) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.
Passage Bio currently has a consensus price target of $9.00, suggesting a potential upside of 675.86%. Athira Pharma has a consensus price target of $19.00, suggesting a potential upside of 660.00%. Given Athira Pharma's higher possible upside, equities research analysts clearly believe Passage Bio is more favorable than Athira Pharma.
Athira Pharma is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.
Athira Pharma's return on equity of -68.53% beat Passage Bio's return on equity.
Passage Bio has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.91, indicating that its share price is 191% more volatile than the S&P 500.
Passage Bio received 30 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 66.67% of users gave Passage Bio an outperform vote while only 58.06% of users gave Athira Pharma an outperform vote.
53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 4.3% of Passage Bio shares are owned by insiders. Comparatively, 19.8% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Passage Bio had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Passage Bio and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.33 beat Passage Bio's score of 0.00 indicating that Passage Bio is being referred to more favorably in the media.
Summary
Passage Bio beats Athira Pharma on 11 of the 14 factors compared between the two stocks.
Get Athira Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athira Pharma Competitors List
Related Companies and Tools
